EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Developments in Leishmaniasis diagnosis: A patent landscape from 2010 to 2022

Daniel Moreira de Avelar, Camila Chaves Santos, Alice Fusaro Faioli iD

PLOS Global Public Health · 01.11.2023 · 3 (11) · e0002557

DOI: 10.1371/journal.pgph.0002557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Global Public Health, online erschienen am 01.11.2023. Verfasst von Daniel Moreira de Avelar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Instituto René Rachou-Fiocruz Minas, Belo Horizonte-MG, Brazil. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Science and Technology Program, FAPEMIG.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current study aims to contribute to the understanding of leishmaniasis diagnosis by providing an overview of patent filings in this field and analyzing whether the methods revealed are consistent with the needs described by the scientific community, in special the main gaps detected by the World Health Organization’s 2021–2030 Roadmap for Neglected Tropical Diseases. To this aim, a patent search was carried out focusing on documents disclosing leishmaniasis diagnostic methods supported by experimental evidence and with earliest priority date from 2010 onwards. Our results show that patenting activity is low and patent families are often formed by individual filings. Most R&D activity occurs in Brazil, which is also the main market of protection. Brazilian academic institutions are the main patent drivers, and collaboration between different institutions is rare. Most patent families describe immunological methods based on ELISA assays, using antibodies directed to K39 and homologues. kDNA is the primary gene for molecular testing. Experimental evidence of test performance in fulfilling critical diagnostic gaps is usually absent. The patent scenario suggests that leishmaniasis diagnostic gaps need to be more closely addressed to drive innovation directed to the control and/or elimination of leishmaniasis. From the public policy point of view, the following strategies are suggested: (i) strengthening collaborative networks, (ii) enhancing the participation of the private sector, and (iii) increasing funding, with special focus on the remaining diagnostic gaps.

Autor:innen und Institutionen

  • Instituto René Rachou-Fiocruz Minas, Belo Horizonte-MG, Brazil.
  • Instituto Nacional de Propriedade Intelectual-INPI, Rio de Janeiro-RJ, Brazil.
  • Fundação Oswaldo Cruz-Fiocruz, Centro de Desenvolvimento Tecnológico em Saúde, Instituto Nacional de Ciência e Tecnologia de Inovação em Doenças de Populações Negligenciadas, Rio de Janeiro, RJ, Brasil.

ORCID-Profile: Alice Fusaro Faioli

Förderung

  • National Institutes of Science and Technology Program
  • FAPEMIG

Zitieren

APA

de Avelar, D. M., Santos, C. C., & Fusaro Faioli, A. (2023). Developments in Leishmaniasis diagnosis: A patent landscape from 2010 to 2022. PLOS Global Public Health, 3(11), e0002557. https://doi.org/10.1371/journal.pgph.0002557

Vancouver

de Avelar DM, Santos CC, Fusaro Faioli A. Developments in Leishmaniasis diagnosis: A patent landscape from 2010 to 2022. PLOS Global Public Health. 2023;3(11):e0002557. doi:10.1371/journal.pgph.0002557

BibTeX
@article{deAvelar2023,
  author = {de Avelar, Daniel Moreira and Santos, Camila Chaves and Fusaro Faioli, Alice},
  title = {Developments in Leishmaniasis diagnosis: A patent landscape from 2010 to 2022},
  journal = {PLOS Global Public Health},
  year = {2023},
  volume = {3},
  number = {11},
  pages = {e0002557},
  doi = {10.1371/journal.pgph.0002557}
}
Kostenlos starten →